{
    "title": "Valeant looks to trim debt pile with $930 mln iNova sale",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4584320/Valeant-sell-iNova-Pharma-business-930-mln.html",
    "date": "2017-06-08",
    "keywords": [
        "valeant",
        "papa",
        "debt",
        "business",
        "grover",
        "thursday",
        "year",
        "divya",
        "deal",
        "amp",
        "sale",
        "co",
        "reporting",
        "june",
        "inc",
        "executive",
        "joseph",
        "pile",
        "dermatology",
        "eye",
        "care",
        "spate",
        "ceo",
        "mike",
        "pearson",
        "goal",
        "interview",
        "place",
        "range",
        "august",
        "performance",
        "pace",
        "target",
        "acquisition",
        "stock",
        "tailspin",
        "drug",
        "pricing",
        "strategy",
        "specialty",
        "pharmacy",
        "scrutiny",
        "percent",
        "morning",
        "trading",
        "dendreon",
        "cancer",
        "treatment",
        "skincare",
        "middle",
        "bloomberg",
        "tuesday",
        "bausch",
        "report",
        "stomachdrug",
        "ltd",
        "price",
        "november",
        "salix",
        "prescription",
        "overthecounter",
        "weight",
        "pain",
        "management",
        "cardiology",
        "cough",
        "cold",
        "half",
        "company",
        "equity",
        "group",
        "sachs",
        "adviser",
        "baker",
        "mckenzie",
        "counsel",
        "editing",
        "dasgupta",
        "sai",
        "sachin",
        "ravikumar"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}